Study shows that dipyridamole is not a strong inhibitor of the SARS-CoV-2 main protease, Mpro.

Key Messages

In this study, the authors Ma and Wang disagree with Li et. al.’s (2020) conclusion that dipyridamole is a potent inhibitor of the SARS-CoV-2 protease Mpro. Instead, based on their experiments, they conclude dipyridamole is only a weak inhibitor of SARS-CoV-2 main protease Mpro, thus leaving its anti-COVID-19 activity unexplained.

Li et al (2021) respond with a critique of the methods used by Ma and Wang and reiterate their original findings.

Proceedings of the National Academy of Sciences

Publication Date: February 23, 2021
Peer Reviewed: Yes
Publication Type: Original | Preclinical

Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors

Chunlong Ma, Jun Wang